# A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease

> **NCT03007888** · PHASE2 · COMPLETED · sponsor: **Impax Laboratories, LLC** · enrollment: 28 (actual)

## Conditions studied

- Advanced Parkinson's Disease

## Interventions

- **DRUG:** Sinemet
- **DRUG:** IPX203

## Key facts

- **NCT ID:** NCT03007888
- **Lead sponsor:** Impax Laboratories, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-14
- **Primary completion:** 2017-08-01
- **Final completion:** 2017-08-01
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2022-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03007888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03007888, "A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03007888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*